Drugs / Vocimagene Amiretrorepvec
Vocimagene Amiretrorepvec
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04089163 | Dec 2019 → Jan 2022 | urinary bladder cancer | Tocagen Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02598011 | Jan 2017 → Nov 2022 | malignant glioma | Tocagen Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02576665 | Jul 2016 → May 2019 | colorectal cancer, head and neck cancer, high grade astrocytic tumor, lymphoma +7 | Tocagen Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01985256 | Feb 2014 → Mar 2016 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma | Tocagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01470794 | Feb 2012 → Apr 2016 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma | Tocagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04327011 | Feb 2011 → Dec 2019 | astrocytoma (excluding glioblastoma), glioblastoma | Tocagen Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT04105374 | Jan 2020 → Nov 2025 | anaplastic astrocytoma, glioblastoma, oligodendroglioma | NRG Oncology | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02414165 | Nov 2015 → May 2019 | anaplastic astrocytoma, glioblastoma | Tocagen Inc. | Terminated | Missed primary Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-08-02 | Denovo Biopharma LLC | Regulatory United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma denovobiopharma.com ↗
FDA authorized a Phase 2 study of DB107 for the treatment of patients with newly diagnosed high grade glioma |
| 2021-12-14 | Denovo Biopharma LLC | Results Denovo Biopharma LLC Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB107 for a Gene Therapy-Based Medicine denovobiopharma.com ↗
DGM7 has been shown to be associated with response to treatment of recurrent high grade glioma (HGG) with an investigational gene therapy combination treatment, DB107, via retrospective analysis. |
| 2021-11-02 | Denovo Biopharma LLC | Results Denovo Biopharma LLC Announces Multiple Presentations at Major Conferences denovobiopharma.com ↗
Extended benefits in patients with recurrent high grade glioma that continuously receive Toca FC after Toca 511 Treatment |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-02 | Denovo Biopharma LLC | United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma denovobiopharma.com ↗ |
| 2021-12-14 | Denovo Biopharma LLC | Denovo Biopharma LLC Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB107 for a Gene Therapy-Based Medicine denovobiopharma.com ↗ |
| 2021-11-02 | Denovo Biopharma LLC | Denovo Biopharma LLC Announces Multiple Presentations at Major Conferences denovobiopharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vocimagene amiretrorepvec | “Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase” PMID 29762717 ↗ Sep 2018 |
| Known as | Toca 511 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02598011 ↗ |
| Known as | Vocimagen amiretrorepvec | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108627 ↗ |
| Route | Other | “received Toca 511 injected into the resection cavity wall” PMID 29762717 ↗ Sep 2018 |